Quanterix is revolutionizing biomarker analysis through digital technology to support the advancement of precision health. Its ultra-sensitive detection platform, Simoa, empowers researchers to study biomarkers in unprecedented detail, enabling earlier disease detection, improved prognoses, and targeted treatments. This innovation aims to enhance quality of life and extend longevity across generations. Founded in 2007 and based in Billerica, Massachusetts, Quanterix’s technology is widely used in research across oncology, neurology, cardiology, inflammation, and infectious diseases.